Research progress of serine hydroxymethyltransferase inhibitors in tumor treatment
10.12025/j.issn.1008-6358.2025.20241030
- VernacularTitle:丝氨酸羟甲基转移酶抑制剂在肿瘤治疗中的研究进展
- Author:
Yili CHEN
1
;
Peisen WANG
1
;
Yuling CHEN
1
;
Yuanyuan ZENG
1
Author Information
1. Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu, China.
- Publication Type:Review
- Keywords:
tumor;
serine metabolism;
serine hydroxymethyltransferase inhibitor
- From:
Chinese Journal of Clinical Medicine
2025;32(1):125-134
- CountryChina
- Language:Chinese
-
Abstract:
Tumor is the result of long-term and unlimited proliferation of cells. Tumor cells adjust various metabolic fluxes to meet increased bioenergy and biosynthetic requirements. Serine is one of the eight non-essential amino acids in the human body. It plays an important role in a variety of physiological activities and can provide one carbon unit, glycine, etc. for cell proliferation. Serine hydroxymethyltransferase (SHMT) is a key enzyme that catalyzes the conversion of glycine and serine. It is highly expressed in a variety of tumors and is a potential target for anti-tumor drugs. This article focuses on the potential of SHMT as a new target for cancer treatment and the preliminary application of its inhibitors in preclinical studies of tumors, providing reference for the development of new targeted drugs for tumors.
